for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aprea Therapeutics Inc

APRE.O

Latest Trade

29.58USD

Change

0.00(0.00%)

Volume

84,978

Today's Range

28.54

 - 

31.00

52 Week Range

15.10

 - 

32.05

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
29.58
Open
29.85
Volume
84,978
3M AVG Volume
--
Today's High
31.00
Today's Low
28.54
52 Week High
32.05
52 Week Low
15.10
Shares Out (MIL)
19.88
Market Cap (MIL)
626.57
Forward P/E
-10.22
Dividend (Yield %)
--

Latest Developments

More

Aprea Therapeutics Inc Qtrly Net Loss Per Share, Basic And Diluted $5.29

Healthcap Vii Lp Reports 11.9 % Stake In Aprea Therapeutics

Aprea Therapeutics Shares Debut about 3.1% over IPO price

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aprea Therapeutics Inc

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.

Industry

Biotechnology & Drugs

Contact Info

535 Boylston St

+1.609.5104718

https://www.aprea.com/

Key Stats

2.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019(E)

0.0K
EPS (USD)

2019(E)

-2.920
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Biotechnology firm ADC pulls listing amid latest IPO market jitters

Biotechnology company ADC Therapeutics SA <ADCT.N> postponed its planned $200 million U.S. initial public offering on Wednesday, citing adverse market conditions as it became the third company to pull a planned IPO in recent days.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up